These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


666 related items for PubMed ID: 15109355

  • 1. Almotriptan improves response rates when treatment is within 1 hour of migraine onset.
    Dowson AJ, Massiou H, Lainez JM, Cabarrocas X.
    Headache; 2004 Apr; 44(4):318-22. PubMed ID: 15109355
    [Abstract] [Full Text] [Related]

  • 2. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.
    Diener HC, Gendolla A, Gebert I, Beneke M.
    Headache; 2005 Apr; 45(7):874-82. PubMed ID: 15985104
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
    Mathew NT, Finlayson G, Smith TR, Cady RK, Adelman J, Mao L, Wright P, Greenberg SJ, AEGIS Investigator Study Group.
    Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.
    Winner P, Rothner AD, Wooten JD, Webster C, Ames M.
    Headache; 2006 Feb; 46(2):212-22. PubMed ID: 16492230
    [Abstract] [Full Text] [Related]

  • 9. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial.
    Freitag F, Smith T, Mathew N, Rupnow M, Greenberg S, Mao L, Finlayson G, Wright P, Biondi D, AEGIS Investigator Study Group.
    Headache; 2008 Mar; 48(3):341-54. PubMed ID: 18302700
    [Abstract] [Full Text] [Related]

  • 10. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study.
    Tepper SJ, Cady R, Dodick D, Freitag FG, Hutchinson SL, Twomey C, Kuhn TA.
    Headache; 2006 Jan; 46(1):115-24. PubMed ID: 16412159
    [Abstract] [Full Text] [Related]

  • 11. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
    Mathew NT, Landy S, Stark S, Tietjen GE, Derosier FJ, White J, Lener SE, Bukenya D.
    Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
    [Abstract] [Full Text] [Related]

  • 12. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines.
    Diamond ML, Cady RK, Mao L, Biondi DM, Finlayson G, Greenberg SJ, Wright P.
    Headache; 2008 Feb; 48(2):248-58. PubMed ID: 18234046
    [Abstract] [Full Text] [Related]

  • 13. The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine.
    Goadsby PJ.
    Cephalalgia; 2008 Sep; 28 Suppl 2():36-41. PubMed ID: 18715331
    [Abstract] [Full Text] [Related]

  • 14. Predictors of migraine headache recurrence: a pooled analysis from the eletriptan database.
    Dodick DW, Lipton RB, Goadsby PJ, Tfelt-Hansen P, Ferrari MD, Diener HC, Almas M, Albert KS, Parsons B.
    Headache; 2008 Feb; 48(2):184-93. PubMed ID: 18234045
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 34.